Tyra Biosciences, Inc.·4

Sep 17, 4:42 PM ET

CHEN ISAN 4

4 · Tyra Biosciences, Inc. · Filed Sep 17, 2021

Insider Transaction Report

Form 4
Period: 2021-09-17
CHEN ISAN
Director
Transactions
  • Conversion

    Series A Preferred Stock

    2021-09-1716,3660 total
    Common Stock (42,509 underlying)
  • Conversion

    Common Stock

    2021-09-17+61,444192,783 total
  • Conversion

    Series B Preferred Stock

    2021-09-177,2900 total
    Common Stock (18,935 underlying)
Footnotes (2)
  • [F1]On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
  • [F2]Includes 37,105 shares subject to repurchase by us, which are subject to vesting.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION